Orçun ÇELİK, Mert Ali KARADAĞ, Murat AKAND, Kürşat ÇEÇEN, ASLAN DEMİR, RAMAZAN KOCAASLAN

Aşırı aktif mesanede farmakoterapiye güncel bakış

Aşırı aktif mesane (AAM) hayat kalitesi üzerine belirgin etkisi olan yaygın bir tıbbi durumdur. Tedavi yaklaşımı davranışsal ve farmakolojiktir. İlk farmakolojik tedavi alternatifi tolerabilitesi, etkinliği ve uzun dönem komplians gibi sınırlayıcı faktörleri olan antikolinerjik ajanlardır. AAM' nin patofizyolojisinin anlaşılması ve farmakolojik tedavideki alternatif ajan arayışı, bu durumun tedavisi için yeni moleküllerin geliştirilmesini sağlamıştır. Bu moleküllerin antikolinerjik ilaçlarla benzer etkileri olup, yan etkilerinden kaçınmaktadırlar.

Current evaluation of pharmacotherapy for overactive bladder

Overactive bladder (OAB) is a prevalent condition that has a significant impact on quality of life. The usual treatment approach is both behavioral and pharmacological. The first-line pharmacological treatment commonly utilizes anticholinergic agents, which may be limited by their tolerability, efficacy, and long-term compliance. Developments in elucidating the pathophysiology of OAB and alternative targets for pharmacological therapy have led to newer agents being developed to manage this condition. These agents which have alternate mechanism of action and avoid the anticholinergic side effects.

PDF

___

1.Wein AJ, Rackley RR. Overactive bladder: a better understanding of pathophysiology, diagnosis and management. J Urol 2006; 175:5-10.
2.Lenderking WR, Nackley JF, Anderson RB, et al. A review of the quality of life aspects of urinary urge incontinence. Pharmacoeconomics 1996; 9:11-23.
3.Tarcan T. Aşırı aktif mesane sendromu. Turk Clin Surg Med Sci 2005; 5:49-55.
4.Schröder A, Abrams P, Andersson K, et al. Chapple CR,Drake MJ, et al. Guidelines on Urinary incontinence. European Associtation of Urology, 2010.
5.Wang P, Luthin GR, Ruggieri MR. Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J Pharmacol Exp Ther 1995; 273:959-66.
6.Lai HH, Boone T, Appell RA. Selecting a medical therapy for overactive bladder. Rev Urol 2002; 4:28-37.
7.Sellers DJ, McKay N. Developments in the pharmacotherapy of the overactive bladder. Curr Opin Urol 2007; 17:223-30.
8.Glickman S, Tsokkos N, Shah PJ. Intravesical atropine and suppression of detrusor hypercontractility in the neuropathic bladder. A preliminary study. Paraplegia 1995; 33:36-9.
9.Thüroff JW, Chartier-Kastler KE, Corcus J, et al. Medical treatment and medical side effects in urinary incontinence in the elderly. World J Urol 1998; 16:48-61.
10.Appell RA. Pharmacotherapy for overactive bladder. Drugs 2006; 66:1361-70.
11.Moore KH. Step-by-step guide to treatment of overactive bladder (OAB)/Detrusor overactivity. In. Urogynecology: Evidence-Based clinical practice. Ed. Springer-Verlag London Ltd. 2006; 77-89.
12.Diokno A, Ingber M. Oxybutynin in detrusor overactivity. Urol Clin N Am 2006; 33:439-45.
13.Andersson KE, Chapple CR. Oxybutynin and the overactive bladder. World J Urol 2001; 19:319-23.
14.Gupta SK, Sathyan G. Pharmacokinetics of an oral once a day controlled release oxybutynin formulation compared with immediate release oxybutynin. J Clin Pharmacol 1999; 39:289-96.
15.Versi E, Appell R, Mobley D, et al. Dry mouth with conventional and controlled release oxybutynin in urinary incontinence. The ditropan XL study group. Obstet Gynecol 2000; 95:718-21.
16.Sand PK. The evolution of transdermal therapy for overactive bladder. Curr Urol Rep 2009; 10:338-41.
17.Hussain RM, Hartigan-Go K, Thomas SH, et al. Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinence. Br J Clin Pharmacol 1996; 41:735.
18.Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU 2007; 100:987- 1006.
19.Appell RA, Abrams A, Drutz HP, et al. Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine. World J Urol 2001; 19:141-7.
20.Kerrebroeck V, Kreder J, Jonas U,et al. Tolterodine once daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology 2001; 57:414- 21.
21.Malone-Lee J, Shaffu B, Anand C,et al. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or order with overactive bladder: a randomized controlled trial. J Urol 2000; 165:1452-6.
22.Appell RA, Sand P, Dmochowski R, et al. Prospective randomised controlled trial of extended release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: result of the OBJECT study. Mayo Clin Proc 2001; 76:358-63.
23.Diokno AC, Appell RA, Sand PK, et al.Prospective, randomised, double blind study of the efficacy and tolerability of the extended release formulations of oxybutynin and tolterodine for overactive bladder: result of the OPERA trial. Mayo Clin Proc 2003; 78:687-95.
24.Fröhlich G, Bulitta M, Strösser W. Trospium chloride in patients with detrusor overactivity. Int J Clin Pharmacol Ther 2002; 40:295-303.
25.Halaska M, Ralph G, Wiedemann A, et al. Controlled double blind multicentre clinical trial to investigate long term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 2003; 20:392-9.
26.Cardozo L, Chapple CR, Toozs-Hobson P, et al. Efficacy of trospium chloride in patients with detrusor instability. Br J Urol 2000; 85:659-64.
27.Zinner N, Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2001; 171:2311-5.
28.Rudy D, Cline K, Harris R, et al. Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urolgy 2006; 67:275-80.
29.Lam S, Hilas O. Pharmacologic management of overactive bladder. Clin Int Aging 2007; 2:337-45.
30.Chughtai B, Levin R, De E. Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacine. Clin Int Aging 2008; 3:503-9.
31.Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well tolerated once daily treatment for averactive bladder. Eur Urol 2004; 45:420-9.
32.Steers W, Corcos J, Foote J, et al. An investigation of dose titration with darifenacine, an M3 selective receptor antagonist. BJU Int 2005; 95:580-6.
33.Hill S, Elhilali M, Millard RJ, et al. Long term darifenacin treatment for overactive bladder in patients aged 65 years and older: analyses of results from a 2 year, opeblabel extention study. Curr Med Res Opin 2007; 23:2697- 704.
34.Zinner N, Tuttle J, Marks L. Efficacy and tolerability of darifenasin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World J Urol 2005; 23:248-52.
35.Simpson D, Wagstaff AJ. Solifenacin in overactive bladder syndrome. Drugs Aging 2005; 22:1061-9.
36.Cardozo L, Hesdörfer E, Milani R, et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double blind, placebo controlled, rising dose trial. BJU Int 2008; 102:1120-7.
37.Yamaguchi O, Marui E, Kakizaki H, et al. Randomised, double blind placebo and propiverine controlled trial of the once daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU Int 2007; 100:579-87.
38.Chapple CR, Rechberger T, Al-Shukri S, et al. Randomised double blind placebo and tolterodin controlled trial of the once daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU 2004; 9:303-10.
39.Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005; 48:464-70.
40.Cole P. Fesoterodine, an advanced antimuscarinic for the treatment of overactive bladder: a safety update. Drugs Fut 2004; 29:715-20.
41.Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for treatment of overactive bladder syndrome. Expert Opin Pharmacother 2008; 9:1787-96.
42.Chapple CR, Van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety and tolerability of once daily fesoterodine in subjects with overactive bladder. Eur Urol 2007; 52:1204-12.
43.Van Kerrebroeck PE, Heesakkers J, Berriman S, et al. Long-term safety, tolerability and efficacy of fesoterodine treatment in subjects with overactive bladder symptoms. Int J Clin Pract 2010; 19:589-93.
44.Madersbacher H, Halaska M, Voigt R, et al. A placebo controlled multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int 1999; 84:646-51.
45.Madersbacher H, Mürtz G. Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (nonneurogenic and neurogenic). World J Urol 2001; 19:324-35.
46.Jünemann KP, Hessdoerfer E, Oparah UI. Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Neurourol Urodyn 2004; 23:599-600.
47.Matthiesen TB, Rittig S, Nørgaard JP, et al. Nocturnal polyuria and natriuresis in male patients with nocturia and lower urinary tract symptoms. J Urol 1996; 156:1292- 9.
48.Asplund R, Aberg H. Diurnal variation in the levels of antidiuretic hormone in elderly subjects with nocturia. J Intern Med 1991; 229:131-4.
49.Weiss JP, Blaivas JG, Jones M, et al. Age related pathogenesis of nocturia in patients with overactive bladder. J Urol 2007; 178:548-51.
50.Darblade B, Behr-Roussel D, Oger S, et al. Effect of potassium channel modulators on human detrusor smooth muscle myogenic phasic contractile activity: potential therapeutic targets for overactive bladder. Urology 2006; 68:442-8.
51.Mora TC, Suarez-Kurtz G. Effects of NS1608, a Calcium channel agonist, on the contractility of guinea pig urinary bladder in vitro. Br Pharmacol 2005; 144:636-41.
52.Morimura K, Yamamura H, Ohya S, et al. Voltage dependent Ca2+ channel block by openers of intermediate and small conductance Ca2+ activated K+ channels in urinary bladder smooth muscle cells. J Pharmacol Sci 2006; 100:237-41.
53.Fredericks CM, Green RL, Anderson GF. Comparative in vitro effects of imipramine, oxybutynin and flavoxate on rabbit detrusor. Urology 1978; 12:487-91.
54.Tomasi PA, Siracusano S, Monni AM, et al. Decreased nocturnal urinary antidiuretic hormone extrection in enuresis is increased by imipramine. BJU Int 2001; 88:932- 7.
55.Sarko J. Antidepresants, old and new. A review of their adverse effects and toxicity in overdose. Emerg Med Clin North Am 2000; 4:637-54.
56.Andersson KE, Sarawate C, Kahler KH, et al. Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder. BJU Int 2010; 106:268-74.
57.Serra DB, Affrime MB, Bedigian MP, et al. QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder. J Clin Pharmacol 2005; 45:1038-47.
58.McDonagh MS, Selover D, Santa J, et al. Drug class review: agents for overactive bladder. Final report. Update 4. Portland, Oregon: Oregon Health & Science University, March 2009.
59.Nijman RJ, Borgstein NG, Ellsworth P, et al. Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials. J Urol 2005; 173:1334-9.
60.Marschall-Kehrel D, Feustel C, Persson de Geeter C, et al. Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial. Eur Urol 2009; 55:729-36.